Department of Internal Medicine, The Catholic University of Korea, College of Medicine, Seoul, Korea.
Am J Rhinol Allergy. 2013 Jan;27(1):e11-6. doi: 10.2500/ajra.2013.27.3853.
Oral tolerance (OT) is considered as a preventive and therapeutic strategy for treating asthma and allergic rhinitis (AR). We investigated the preventive effects of OT on allergic inflammation and remodeling in the upper and lower airways in a mouse model of allergy.
BALB/c mice were divided into four groups: control, allergy, low-dose OT, and high-dose OT. To induce OT, mice were fed ovalbumin (OVA) before sensitization with OVA/Al(OH)(3) at a dose of 1 mg for 6 days in low-dose OT group and a single dose of 25 mg in high-dose OT group. After sensitization followed by OVA challenge, nasal symptoms, interleukin (IL)-13, interferon (IFN)-gamma, IL-10, and transforming growth factor (TGF) beta-1 levels in nasal lavage (NAL) and bronchoalveolar lavage (BAL) fluids were measured, and OVA-specific IgE, IgG1, and IgG2a levels were measured in the serum. The airway hyperresponsiveness (AHR) was measured by enhanced pause. The goblet cell hyperplasia and the thickness of lamina propria were observed in the upper and lower airways.
In the allergy group, the allergic behavior scores, AHR, and OVA-specific IgE, IgG1, and IgG2a levels; inflammatory cells; IFN-gamma levels; and IL-13 levels in NAL/BAL fluids were elevated compared with the control group, low-dose OT group, and high-dose OT group. The allergy group had higher levels of IL-10 and TGF-beta-1 in BAL fluids when compared with the other groups. The goblet cell hyperplasia and the thickness of the lamina propria were attenuated in both OT groups compared with the allergy group.
OT may effectively prevent AHR, allergic inflammation, and airway remodeling in the upper and lower airways.
口服耐受(OT)被认为是治疗哮喘和过敏性鼻炎(AR)的一种预防和治疗策略。我们在过敏小鼠模型中研究了 OT 对上下呼吸道过敏炎症和重塑的预防作用。
BALB/c 小鼠分为四组:对照组、过敏组、低剂量 OT 组和高剂量 OT 组。为了诱导 OT,在低剂量 OT 组中,在致敏前用 1mg OVA/Al(OH)(3) 喂养小鼠 6 天,在高剂量 OT 组中用 25mg OVA/Al(OH)(3) 喂养小鼠 1 次。致敏后用 OVA 激发,测量鼻症状、鼻灌洗液(NAL)和支气管肺泡灌洗液(BAL)中白细胞介素(IL)-13、干扰素(IFN)-γ、IL-10 和转化生长因子(TGF)β-1 水平,以及血清中 OVA 特异性 IgE、IgG1 和 IgG2a 水平。通过增强暂停测量气道高反应性(AHR)。观察上下气道的杯状细胞增生和固有层厚度。
与对照组、低剂量 OT 组和高剂量 OT 组相比,过敏组的过敏行为评分、AHR 以及 OVA 特异性 IgE、IgG1 和 IgG2a 水平、炎症细胞、NAL/BAL 液中的 IFN-γ 水平和 IL-13 水平均升高,BAL 液中 IL-10 和 TGF-β-1 水平也高于其他组。与过敏组相比,OT 组的杯状细胞增生和固有层厚度均减轻。
OT 可能有效预防上下呼吸道的 AHR、过敏炎症和气道重塑。